Home
Billing codes
J9223

PAYER POLICY CHANGES

J9223 Insurance Policy Changes

HCPCS J9223 is officially defined as "Injection, lurbinectedin, 0.1 mg." HCPCS J9223 is referenced in 12 tracked payer policy changes from Florida Blue, Highmark, and 5 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9223 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Florida Blue · Effective Jun 1, 2026High impact
New Drug Waste Reduction Guideline
Florida Blue, in collaboration with Prime Therapeutics Medical Pharmacy Solutions, began a Drug Waste Reduction Guideline for select provider-administered medications on June 1, 2026. Under the guideline, the medication dose must align to the most efficient vial size combination when clinically appropriate, and it applies to all Florida Blue and Truli for Health commercial plans. For prior authorization requests on listed medications, the optimized dose cannot be bypassed, and the request moves to pending status for additional clinical review.
Highmark · Effective May 1, 2026High impact
Prior Authorization Changes to Oncology-related Codes
Effective May 1, 2026, Highmark is adding 115 oncology-related codes to their prior authorization requirement list, including common chemotherapy medications and radiation therapy procedures. All authorization requests for these codes must be submitted electronically through Availity Essentials and will be reviewed by Evolent as part of Highmark's oncology value-based care strategy.
WellCare · Effective Jan 1, 2026High impact
[Georgia] Prior Authorization Update for Evolent: Effective January 1, 2026 (PDF)
Beginning January 1, 2026, the procedure codes in this Centene bulletin require prior authorization through Evolent, which manages prior authorizations for Centene in medical oncology, radiation oncology, pediatric and dose optimization, and cardiology. The change applies to all Ambetter (Marketplace), Medicaid and Medicare products offered by Centene. The code table includes anti-emetics, bone metastasis drugs, cancer treatment drugs, and supportive medications such as iron products, ESAs, myeloid growth factors and immune globulins.
Florida Blue · Effective Oct 1, 2026Medium impact
Fee Schedule Change for Certain Physician-Administered Drug Program Medications
Florida Blue updated reimbursement for about 60 physician-administered drug codes in its Physician-Administered Drug Program, administered by Prime Therapeutics Management Medical Pharmacy Solutions, effective October 1, 2026. That date has already passed as of November 4, 2026, so the new rates should already be in use for the affected Florida Blue HMO, PPO, State Employees PPO and Truli for Health claims, and the practice should confirm its drug fee schedule reflects them.
Independence Blue Cross · Effective Jun 1, 2026Medium impact
MA08.125d, Lurbinectedin (Zepzelca®)
Independence Blue Cross updated MA08.125d to remove specific lung cancer ICD-10 diagnosis codes (C33, C34.xx series) and now requires providers to report the most appropriate diagnosis code supporting medical necessity criteria. Coverage for Lurbinectedin (Zepzelca®) for small cell lung cancer treatment remains substantively unchanged, but diagnosis code reporting is now more flexible and less prescriptive. This change affects all SCLC claims billed under this policy effective June 1, 2026.
Independence Blue Cross · Effective Jun 1, 2026Medium impact
08.01.67d, Lurbinectedin (Zepzelca®)
Independence Blue Cross updated policy 08.01.67d for Lurbinectedin (Zepzelca®) effective June 1, 2026, removing specific ICD-10 lung cancer diagnosis codes (C33, C34.xx series) and requiring providers to report the most appropriate diagnosis code supporting medical necessity criteria instead. Coverage remains for small cell lung cancer treatment in specific clinical scenarios per FDA and NCCN guidelines.
Aetna · Identified Aug 16, 2026Medium impact
Lurbinectedin (Zepzelca) (CPB 0978, reviewed 2026-03-11)
Aetna considers lurbinectedin (Zepzelca) medically necessary for small cell lung cancer in these regimens: as a single agent for subsequent treatment after relapse, primary progressive disease, or metastatic disease that progressed on or after platinum-based chemotherapy; or in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs as maintenance treatment for extensive stage disease when there is no progression after first-line induction with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. Aetna considers lurbinectedin experimental, investigational, or unproven for breast cancer, endometrial cancer, macular edema, neuroendocrine carcinoma, non-small cell lung cancer and ovarian cancer.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
State and School Employees' Health Insurance Plan - Injectable Oncology
Injectable oncology drugs under the medical benefit may be considered medically necessary when FDA-approved or compendia-supported use criteria are met, including NCCN Compendium level of evidence 1 or 2A, first-line failure or intolerance, required genetic testing, combination use where applicable, and dosage within program quantity limits. Many named agents, including Anktiva, Blenrep, Boruzu, Keytruda Qlex, Lymphir, and Lunsumio Velo, are listed as not covered on the State Health Plan Medical Drug Formulary. The 11/01/2026 update added coverage for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the 10/19/2026 update added coverage for Tivdak (tisotumab vedotin-tftv), and the 06/15/2026 update added several agents to the not medically necessary list.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Injectable Oncology
Prior authorization is required for the injectable oncology medications listed in this BCBSMS policy, and the requested agent must meet the policy's medical necessity criteria. The 10/19/2026 update added coverage for Tivdak (tisotumab vedotin-tftv), and the 11/01/2026 update added coverage for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) and listed Lunsumio Velo (mosunetuzumab-axgb) as a non-covered medication. Several other listed drugs are not medically necessary for all indications because other formulary alternatives are covered by the plan.
Premera Blue Cross · Identified Jun 18, 2026Medium impact
Medical Policy and Coding Updates - January 2021
Effective January 1, 2021, Immune Globulin Therapy criteria changed so that preventive IVIG use after hematopoietic cell transplantation, in chronic lymphocytic leukemia, lymphoma, multiple myeloma and solid organ transplant became investigational, and IVIG for humoral immunodeficiency states now requires an IgG level below 400 mg/dL with persistent or recurrent infections. Effective January 1, 2021, the Drugs for Weight Management policy was added for Contrave, Qsymia, Saxenda and Xenical for groups that cover weight loss drugs, and the Exception Request policy for Washington fully insured members was added. Coding updates made CPT 69705, 69706 and 55880, and HCPCS Q5122, J9316, J7352, J0638 and J1823 subject to medical necessity and prior authorization review, and made the listed AIM genetic testing codes subject to prior authorization starting January 1, 2021.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA08.125c, Lurbinectedin (Zepzelca®)
Independence Blue Cross reissued policy MA08.125c for lurbinectedin (Zepzelca®) on 05/28/2025 to communicate the Company's continuing coverage position for small cell lung cancer treatment. This is a policy reissuance with no substantive coverage changes from the prior version (MA08.125d supersedes this activity entry). The billing team should verify they are using MA08.125d, not the superseded MA08.125c version, for all current claim adjudication.
Independence Blue Cross · Identified Jun 19, 2026Low impact
08.01.67c, Lurbinectedin (Zepzelca®)
Independence Blue Cross reissued policy 08.01.67d for lurbinectedin (Zepzelca®) to communicate continuing coverage position for small cell lung cancer treatment. The policy maintains coverage for primary treatment maintenance therapy, subsequent systemic therapy, and progression/relapse scenarios with specific clinical criteria. No substantive coverage changes from prior version 08.01.67c; this is a routine reissue.

Watch J9223

Get one email when a payer policy names J9223, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

REFERENCE DATA

Payers with rules19

Payers requiring prior auth19

Aetna · Effective November 1, 2026
Prior authorization required
Participating provider precertification list for Aetna
Anthem BCBS · Effective November 1, 2026
Prior authorization required
Anthem Local PPO Precertification/Prior Authorization List (California | Anthem Blue Cross | Commercial)
Fidelis Care · Effective November 1, 2026
Prior authorization required
Fidelis Care Metal-Level Products authorization grid

FREQUENTLY ASKED QUESTIONS

Does Aetna require prior authorization for J9223?

Aetna lists J9223 on Participating provider precertification list for Aetna for commercial plans (list dated November 1, 2026). Verify with the payer before scheduling.

Does Ambetter require prior authorization for J9223?

Ambetter lists J9223 on Ambetter from Arizona Complete Health CMS-0057-F prior authorization requirements for exchange plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does AmeriHealth Caritas require prior authorization for J9223?

AmeriHealth Caritas lists J9223 on AmeriHealth Caritas Louisiana prior authorization service list for medicaid managed plans. Verify with the payer before scheduling.

Does Anthem BCBS require prior authorization for J9223?

Anthem BCBS lists J9223 on Anthem Local PPO Precertification/Prior Authorization List (California | Anthem Blue Cross | Commercial) for commercial plans (list dated November 1, 2026). Verify with the payer before scheduling.

Does Arizona Complete Health require prior authorization for J9223?

Arizona Complete Health lists J9223 on Arizona Complete Health CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

What insurance policy changes affect HCPCS J9223?

There are 12 tracked policy changes affecting HCPCS J9223, including updates from Florida Blue, Highmark, WellCare. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9223?

Payers that have issued tracked updates for HCPCS J9223 include: Florida Blue, Highmark, WellCare, Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi, Premera Blue Cross.

How do I get notified when HCPCS J9223 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9223. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for HCPCS J9223?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

See every payer rule for J9223

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J9223 in one place.

See every payer rule

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

New Drug Waste Reduction Guideline

Prior Authorization Changes to Oncology-related Codes

[Georgia] Prior Authorization Update for Evolent: Effective January 1, 2026 (PDF)

Fee Schedule Change for Certain Physician-Administered Drug Program Medications

MA08.125d, Lurbinectedin (Zepzelca®)

08.01.67d, Lurbinectedin (Zepzelca®)

Lurbinectedin (Zepzelca) (CPB 0978, reviewed 2026-03-11)

State and School Employees' Health Insurance Plan - Injectable Oncology

Injectable Oncology

Medical Policy and Coding Updates - January 2021

MA08.125c, Lurbinectedin (Zepzelca®)

08.01.67c, Lurbinectedin (Zepzelca®)

Prior authorization required

Prior authorization required

Prior authorization required

Does Aetna require prior authorization for J9223?

Does Ambetter require prior authorization for J9223?

Does AmeriHealth Caritas require prior authorization for J9223?

Does Anthem BCBS require prior authorization for J9223?

Does Arizona Complete Health require prior authorization for J9223?

What insurance policy changes affect HCPCS J9223?

Which payers have updated policy for HCPCS J9223?

How do I get notified when HCPCS J9223 policy changes?

Why do payers change policies for HCPCS J9223?